Drugs / Epo
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01235923 Comparator | Apr 2006 → Mar 2009 | — | University of New Mexico | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Epo | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01235923 ↗ |
| Modality | Protein / enzyme biologic | “human recombinant erythropoietin (Epo)” NCT01235923 ↗ |
| Route | Subcutaneous | “Epo 400 units/kg administered subcutaneously three times per week for a total of 4 weeks” NCT01235923 ↗ |